UNUlf P. Neumann

Ulf P. Neumann

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ulf P. Neumann has a total of 97 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 August 2015
      • Vol. 13  (4) , 301-8

    Liver Transplant for Cholangiocarcinoma: A Comeback?

    by Maximilian Schmeding, Ulf P Neumann

    Liver transplant is not a standard therapy for cholangiocarcinoma; complete surgical resection of the tumor is currently the treatment of choice. Palliative options offer only short-term survival. After initial recurrence rates after liver transplant for cholangiocarcinoma in the 1990s were unacceptably high, cholangiocarcinoma has been regarded widely as a contraindication to liver transplant. Ubiquitous organ shortage further supports this conviction. Careful patient selection and a rigorous perioperative treatment by radiochemotherapy have produced some impressive survival data in specialized transplant centers in recent years. Although the graft shortage is aggravating in the Western world, the issue of liver transplant as a treatment for irresectable cholangiocarcinoma is being discussed. This review article provides an update and overview on the current status of liver transplant as a potential option for patients with irresectable cholangiocarcinoma.


  • Liver transplantation for intra- and extrahepatic cholangiocarcinoma

    by Maximilian Schmeding, Ulf P. Neumann

    Cholangiocarcinoma (CCA) is the second most frequent primary liver malignancy. Despite extensive surgical approaches and recently developed perioperative chemotherapeutic protocols the 5-year- survival rates range from 20-60%. Especially for central intrahepatic CCA resection is often impossible due to bilobar vascular and biliary invasion; patients with primary sclerosing cholangitis often present with small central tumors and significantly impaired liver function. For these patients liver transplantation (LT) has been discussed as a potential curative option. After a series of LT for CCA in the 1990s with high quotas of early tumor recurrence and very limited long-term survival CCA has widely been agreed upon as a contraindication for LT in times of universal organ shortage. However, in selected cases of patients with PSC and small CCA as well as irresectable Klatskin tumor without extrahepatic disease LT has been performed with acceptable recurrence-free survival rates. Modern, aggressive protocols of perioperative treatment have been established with promising results. This article provides an update and overview on the current status of LT as a potential option for patients with irresectable CCA.


    • 1 October 2012
      • Vol. 32  (10) , 4517-21

    Clinical outcome of patients with advanced ovarian cancer after resection of liver metastases.

    by Ulf P Neumann, Christina Fotopoulou, Maximilian Schmeding, Armin Thelen, Georgios Papanikolaou, Elena I Braicu, Peter Neuhaus, Jalid Sehouli

    Hepatic resection has become the standard treatment for patients with primary or metastatic liver malignancies. The aim of our study was to evaluate the clinical outcome of hepatic resection in patients with advanced ovarian cancer (AOC). All patients undergoing hepatic resection for AOC in our institution between 11/1991 and 02/2007 were evaluated by a validated intraoperative documentation tool. Seventy patients were evaluated (median age=59 years; range=29-76 years). Forty-one (58.6%) patients underwent liver resection; 29 patients had unresectable disease. Additional multivisceral procedures performed were: colic resection (51.4%), small bowel resection (32.9%), gastric resection (5.7%), pancreatic resection (4.3%), splenectomy (5.7%). The median survival of patients with R0 resection was 42 months (95% confidence interval (CI)=17-66 months), 4 months for R1, 6 months (95% CI=0-11 months) for R2, and 5 months (95% CI=0-9 months) for those without liver resection. In multivariate analysis, postoperative residual tumor mass was the strongest predictor of survival. Our data indicate that complete macroscopical tumor resection remains the strongest predictor of survival in patients with liver metastases from AOC.


    • 1 February 2011
      • Vol. 9  (1) , 1-6

    Treatment of hepatitis C-virus-reinfection after liver transplant with silibinin in nonresponders to pegylated interferon-based therapy.

    by Dennis Eurich, Marcus Bahra, Thomas Berg, Sabine Boas-Knoop, Michael Biermer, Ruth Neuhaus, Peter Neuhaus, Ulf Neumann

    Hepatitis C-virus-persistence after orthotopic liver transplant leads to reduced patient and graft survival compared to other indications. Current interferon-based antiviral therapy of hepatitis C-virus-infection posttransplant provides a sustained response rate of 30% to 40%. This study, performed in an hepatitis C-virus-reinfected liver transplant population, examines the antiviral effect of intravenously administered silibinin, recently reported to exhibit strong antiviral properties in the natural setting of hepatitis C-virus-related liver disease. Four patients after orthotopic liver transplant with hepatitis C-virus-recurrence, previously having not responded to peg-interferon-ribavirin therapy, were treated with intravenous silibinin and additionally, after the 10th day, with standard interferon-based therapy. Aminotransferases and hepatitis C-virus-RNA were measured during treatment. All patients demonstrated normalization of liver enzymes and significant decline of hepatitis C-virus-RNA measured at day 10 (mean 2.8 logarithmic levels: 1.7, 2.3, 2.9, and 4.3) during silibinin monotherapy. One patient cleared hepatitis C-virus-RNA under silibinin monotherapy and another patient eliminated hepatitis C virus under subsequent interferon-based therapy. No adverse effects were observed during silibinin application. Intravenous silibinin is an effective therapeutic approach for treating hepatitis C-virus-reinfection after liver transplant and should be evaluated further.


  • Open Access

    Hydroxyproline-containing collagen analogs trigger the release and activation of collagen-sequestered proMMP-2 by competition with prodomain-derived peptide P33-42

    by Martin Ruehl, Marion Muche, Christian Freise, Ulrike Erben, Ulf Neumann, Detlef Schuppan, Yury Popov, Walburga Dieterich, Martin Zeitz, Richard W Farndale, et al.

    Fibrolytic and profibrotic activities of the matrix metalloproteinases (MMPs)-2 and -9 play a central role in liver fibrosis. Since binding to the extracellular matrix influences the activity of both gelatinases, here the role of fibrillar collagens as the most abundant matrix components in fibrotic tissue was investigated.


    • 1 June 2010
      • Vol. 8  (2) , 104-10

    Donor influence on outcome in patients undergoing liver transplant for primary biliary cirrhosis.

    by Dietmar A Jacob, Elena Haase, Fritz Klein, Johann Pratschke, Ulf P Neumann, Peter Neuhaus, Marcus Bahra

    Risk factors for survival after liver transplant owing to primary biliary cirrhosis have been extensively investigated, whereas the donor-specific influence and particularly, the histologic data, have not been sufficiently analyzed. Donor data of 121 patients who underwent liver transplant for primary biliary cirrhosis and histologic findings of 69 donor liver grafts were assessed according to preoperative status and histologic criteria. Findings were correlated with the histologic and clinical course up to 20 years after orthotopic liver transplant. Risk factors for death were a longer stay in intensive care units (> 7 days) (P < .02), a hypotensive period > 60 minutes (P < .03), and the administration of red blood cells (P < .04). Grafts from donors with liver fibrosis (P < .03), fatty degeneration (P < .04), and liver cell hydrops (P < .04) resulted in a significantly higher risk of primary biliary cirrhosis recurrence. Log rank analysis revealed a significant decreased survival for patients if donors had a prolonged hypotensive period (P < .02) and administration of epinephrine (P < .03) and red blood cells (P < .05). Our results show that donor histology can affect disease recurrence, especially the grade of inflammation, fibrosis, and fatty degeneration. In addition, prolonged intensive care hospitalization for donors should be avoided.


  • Aging of the liver graft and functional quality in the absence of recurrent disease: A 10 year histological follow-up

    by Ulf P. Neumann

    Although considerable information has been acquired concerning the function of older donor liver grafts it remains unclear how long these organs may fare well in their "cumulative life span". As graft challenge due to recurrent underlying disease can best be eliminated and controlled in patients transplanted for alcoholic liver disease (ALD) we analysed liver biopsies of ALD patients during a 10-year follow-up with special emphasis on donor age and parenchymal quality. Biopsies were taken from 271 patients 1, 3, 5, 10 years after LT. Specimen were analysed and staged concerning inflammation, rejection, fatty involution, and fibrosis/cirrhosis. Donor characteristics were recorded along with clinical and serological parameters, immunosuppressive protocols, rejection episodes, and patient and graft survival. 1, 3, 5 years after LT >80% of patients displayed only minimal fibrosis. In the further course fibrosis rates increased among all patients, with slightly more fibrosis for recurrent drinkers. Donor age did not influence fibrosis progression, long-term patient or graft survival. Regardless of alcohol abuse survival was excellent 5 years after LT, after 10 years abstinent patients did significantly better (82%;68%; p=0.017. LT for ALD offers excellent long-term survival with minimal histological alteration, especially in abstinent patients. Aged organs generate adequate function in ALD recipients.


    • 17 December 2009
      • Vol. 14  (4) , 40-6

    Safety of mycophenolate mofetil monotherapy in patients after liver transplantation.

    by Carsten Kamphues, Roberta Bova, Christoph Röcken, Ruth Neuhaus, Johann Pratschke, Peter Neuhaus, Ulf P Neumann

    Due to the nephrotoxicity of calcineurin inhibitors (CNIs) mycophenolate mofetil (MMF) has become a promising immunosuppressive alternative in recent years. In several studies an improvement of renal function could be reached by introduction of MMF and withdrawal of CNIs but there is few known about the long-term effects of MMF on liver-, kidney- and bone marrow function. We therefore retrospectively reviewed 123 adult liver transplant patients who were successfully converted to MMF monotherapy without any acute rejection within the first three months of MMF monotherapy. Serum levels of liver enzymes as well as white blood cells did not show any significant difference between the time of conversion and after 1 year but a significant reduction in serum creatinine could be evaluated (1.47 mg/dl vs. 1.54 mg/dl). In 59 patients liver biopsies were performed before and after introduction of MMF monotherapy. None displayed signs of chronic rejection during MMF monotherapy but there was a slight increase of the fat content of the liver (16.1% vs. 9.8%). In conclusion after successful conversion to MMF monotherapy this regime is safe and effective and the long-term effects of MMF monotherapy on the liver tissue are minor. Furthermore renal function can be improved without considerable effects on the bone marrow.


    • 1 December 2009
      • Vol. 19  (4) , 349-53

    Traumatized liver grafts for organ donation? A single-center experience.

    by Roberta Bova, Guido Schumacher, Ulf Neumann, Johann Pratschke, Peter Neuhaus, Matthias Glanemann

    Because the number of patients on waiting lists increases each year, new strategies are urgently needed to expand the donor pool. The use of traumatized donor livers for orthotopic liver transplantation at a transplant center is described. After transplantation, no increased incidence of perioperative complications such as bleeding, bile leakage, or liver graft dysfunction were observed and the transplanted livers exhibited appropriate long-term function. Thus, the use of injured livers may offer new opportunities in transplantation.

  • Traumatized liver grafts for organ donation? A single-center experience

    by Roberta Bova, Guido Schumacher, Ulf Neumann, Johann Pratschke, Peter Neuhaus, Matthias Glanemann